Eribulin in breast cancer: Current insights and therapeutic perspectives

Figure 1 Chemical structures of halichondrin B and eribulin mesylate. Eribulin is a structurally-simplified, synthetic, macrocyclic ketone analogue of halichondrin B Citation: Swami U, Shah U, Goel S. Eribulin in Cancer Treatment. Mar Drugs 2015; 13: 5016-5058. Copyright© The Authors 2015. Published by MDPI. The authors have obtained the permission for figure using from the copyright holder (Supplementary material).

Figure 2 Eribulin non-mitotic mechanisms of action in cancer. Eribulin induces phenotypic reversal of epithelial to mesenchymal transition, decreases proportions of cancer stem cells, reduces the immunosuppressive tumour microenvironment and promotes vascular remodelling.